Journal of Vaccine Research 2024, Vol.14, No.3, 135-146 http://medscipublisher.com/index.php/jvr 146 Liao J., and Zhang S., 2021, Safety and efficacy of personalized cancer vaccines in combination with immune checkpoint inhibitors in cancer treatment, Frontiers in Oncology, 11: 663264. https://doi.org/10.3389/fonc.2021.663264 PMid:34123821 PMCid:PMC8193725 Liu Z., Behloul N., Baha S., Wei W., Shi R., and Meng J., 2019, Design and immunogenicity analysis of the combined vaccine against zoonotic hepatitis E and foot-and-mouth disease, Vaccine, 37(46): 6922-6930. https://doi.org/10.1016/j.vaccine.2019.09.036 Lopes A., Vandermeulen G., and Préat V., 2019, Cancer DNA vaccines: current preclinical and clinical developments and future perspectives, Journal of Experimental and Clinical Cancer Research, 38: 1-24. https://doi.org/10.1186/s13046-019-1154-7 Menachery V., Gralinski L.E., Mitchell H., Dinnon K., Leist S., Yount B., McAnarney E.T., Graham R.L., Waters K., and Baric R., 2018, Combination attenuation offers strategy for live attenuated coronavirus vaccines, Journal of Virology, 92(17): 1110-1128. https://doi.org/10.1128/JVI.00710-18 Monrad J., 2020, Ethical considerations for epidemic vaccine trials, Journal of Medical Ethics, 46(7): 465-469. https://doi.org/10.1136/medethics-2020-106235 Nauta J., 2020, Basic concepts of vaccine immunology, Springer Series in Pharmaceutical Statistics, 2020: 3-13. https://doi.org/10.1007/978-3-642-14691-6_1 Obando-Pacheco P., Rivero-Calle I., Raguindin P., and Martinón-Torres F., 2019, DTaP5-HBV-IPV-Hib pediatric hexavalent combination vaccine for use in children from 6 weeks through to 4 years of age, Expert Review of Vaccines, 18: 1115-1126. https://doi.org/10.1080/14760584.2019.1690457 Pulendran B., and Ahmed R., 2011, Immunological mechanisms of vaccination, Nature Immunology, 12(6): 509-517. https://doi.org/10.1038/ni.2039 Ravi M., Krishnamurthy B., James S., Sandhya G., Satish M., and Sahoo D., 2019, Immunogenicity and safety of a liquid pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by human biologicals Institute in 6-8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority study, Vaccine, 37(38): 5714-5721. https://doi.org/10.1016/j.vaccine.2019.06.067 Sellers R., Nelson K., Bennet B.M., Wolf J., Tripathi N., Chamanza R., Perron Lepage M., Adkins K., Laurent S., and Troth S.P., 2020, Scientific and regulatory policy committee points to consider: approaches to the conduct and interpretation of vaccine safety studies for clinical and anatomic pathologists, Toxicologic Pathology, 48(2): 257-276. https://doi.org/10.1177/0192623319875085 Shende P., and Waghchaure M., 2019, Combined vaccines for prophylaxis of infectious conditions, artificial cells, Nanomedicine and Biotechnology, 47(1): 695-704. https://doi.org/10.1080/21691401.2019.1576709 Slack C., ed, 2016, Ethical considerations in vaccine trials in resource-limited settings, Academic Press, USA, pp.447-462 https://doi.org/10.1016/B978-0-12-802174-3.00022-9 Susarla S.K., Gupta M., Mantan M., Dhongade R., Bhave S., Das R., Ray R., Babu T.R., Shende P., and Waghchaure M., 2019, Combined vaccines for prophylaxis of infectious conditions, Artificial Cells Nanomedicine, and Biotechnology, 47(1): 695-704. https://doi.org/10.1080/21691401.2019.1576709 Tickner J., Leman R., and Abramson R., 2007, The role of risk assessment in regulatory decision-making: improved approaches needed, Risk Analysis, 27(2): 409-417. https://doi.org/10.1111/j.1539-6924.2007.00889.x Weir G., Hrytsenko O., Stanford M., Karkada M., Berinstein N., and Mansour M., 2016, Multimodal therapy with a potent vaccine, metronomic cyclophosphamide and anti-PD-1 enhances immunotherapy of advanced tumors by increasing activation and clonal expansion of tumor infiltrating T cells, Cancer Research, 76(14_Supplement): 4903. https://doi.org/10.1158/1538-7445.AM2016-4903 Yao T., Shao Z., Wu L., Dong S., Gao L., Wu Y., Shi X., Shi J., Liu G., Wang J., Zhao H., Guo H., Liu H., Wu X., Liu L., Song X., Zhu J., Zhang Y., Feng Y., Liang X., and Wang S., 2021, Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: a 3-year follow-up study in China, Vaccine, 39(18): 2537-2544. https://doi.org/10.1016/j.vaccine.2021.03.074
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==